Abiomed, Inc. (ABMD) Tops Q3 EPS by 12c; Boosts Lower-End of FY12 Revs Outlook

Abiomed, Inc. (NASDAQ: ABMD) reported Q3 EPS of $0.11, $0.12 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $32.2 million versus the consensus estimate of $31.43 million.

Sees FY2012 revenue of $122-$125 million, versus prior guidance of $120-$125 million and the consensus of $123.3 million.

For earnings history and earnings-related data on Abiomed, Inc. (ABMD) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Range Impact, Inc. (RNGE) Reports Q2 Loss of $0.02
• SuperCom (SPCB) Tops Q3 EPS by 43c